Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dimension Therapeutics Inc.

Division of Ultragenyx Pharmaceutical Inc.

Latest From Dimension Therapeutics Inc.

Biopharma Quarterly Dealmaking Statistics, Q3 2017

Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.

BioPharmaceutical Deals

Asia Executives To Watch: Alcon Japan New President, AZ International EVP

Autumn has brought a flurry of personnel changes with Kyowa FujiFilm getting a new president and AZ a new executive vice president for the international region. Fosun and the medtech firm, Median Technologies, have also seen personnel movement.

Asia Pacific Appointments

Start-Up Quarterly Statistics: Fundraising Fell, But Deal-Making Rose In Q3

A review of biopharma start-up deal-making and financing activity from July through September 2017, based on data from Strategic Transactions, showed that fundraising declined 18% from the previous quarter, however the number of acquisitions doubled to eight.

StartUps and SMEs Financing

Deals Shaping The Medical Industry, October 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2017.

Deals BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Ultragenyx Pharmaceutical Inc.
  • Senior Management
  • Annalisa Jenkins, CEO
    Sam Wadsworth, PhD, CSO
    Andy Hu, MD, Head, Bus. Dev.
    Mary Thistle, COO
    K. Reed Clark, PhD, SVP, Head, Pharmaceutical Dev.
    Eric Crombez, MD, CMO
    Alex Fotopoulos, MSc, SVP, Head Tech Ops.
    Deborah Geraghty, PhD, SVP, Head Corp Strategy
    Robert Gaffey, VP, Finance
    Janet Rae, Head, Global Reg Affairs
    Khandan Baradaran, PhD, Head of Quality
  • Contact Info
  • Dimension Therapeutics Inc.
    Phone: (617) 401-0011
    840 Memorial Dr.
    4th Fl.
    Cambridge, MA 02139